Hostname: page-component-7c8c6479df-r7xzm Total loading time: 0 Render date: 2024-03-28T00:27:25.978Z Has data issue: false hasContentIssue false

Race and prescribing

Published online by Cambridge University Press:  02 January 2018

Anne Connolly*
Affiliation:
Maudsley Hospital, London
*
Rights & Permissions [Opens in a new window]

Summary

Treatment of mental illness in Black and minority ethnic groups differs from that in the White majority. Large differences in admission, detention and seclusion rates have been recorded. These disparities extend into the physical healthcare setting, particularly in the USA but also within the UK National Health Service. There are many influences on prescribing of psychotropic medication, not least the metabolising capacity of the individual. Ethnic differences do occur, particularly for East Asian peoples. However, these differences are broadly similar across ethnic groups, particularly for the cytochrome P450 enzymes responsible for metabolising psychotropic medicines. Psychotropic medication prescribing also differs by ethnicity. Specifically, antipsychotic dose, type and route of administration may differ. However, most data originate in the USA and UK studies have not replicated these findings, even after controlling for multiple confounding factors. Similarly, antidepressant prescribing and access to treatment may differ by ethnicity. These differences may have complex causes that are not well understood. Overall, prescribing of antipsychotics appears to be broadly equitable in Black and minority ethnic groups.

Type
Editorial
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © The Royal College of Psychiatrists, 2010

Treatment of mental illness in Black and minority ethnic groups differs from that in the majority. 1 Large differences in admission, seclusion and detention rates have been measured for different ethnicities - particularly when data from Black and White patients are compared. Specifically, Black patients are almost four times more likely to be detained under the Mental Health Act, Reference Singh, Greenwood, White and Churchill2 up to nine times more likely to be admitted into hospital. 3 Black people also have a longer length of admission 3 and are almost eight times more likely to be treated on a high-security ward. Reference Leese, Thornicroft, Shaw, Thomas, Mohan and Harty4 These differences have complex, often multifactorial causes and have been attributed to misdiagnosis, delays in seeking and receiving treatment, higher incidences of, and exposure to, risk factors for psychosis, Reference Kirkbride, Fearon, Morgan, Dazzan, Morgan and Tarrasch5 and discrimination. Despite the Department of Health's numerous recommendations in its Delivering Race Equality 1 and Inside Outside 6 reports, these differences continue to exist and, accepting the inherent limitations of data collected from a cross-sectional survey, are not improving. 3 Ultimately, these findings have led to accusations, vociferously rejected by many, Reference Singh and Burns7-Reference Singh9 of institutional racism in mental health services. Reference Murray and Feron10

Race and physical healthcare

Differences in the provision of health services to Black and minority ethnic groups can also extend into physical healthcare. 6 Access to treatment may be affected by ethnicity, particularly in the USA but also within the equitable UK healthcare system. Examples of UK healthcare inequality include reduced cervical cancer screening and reduced rates of coronary angioplasty in South Asian populations. Reference McKenzie and Bhui11,Reference Acheson12 There are numerous well-documented differences in the medical treatment of Black and minority ethnic patients in the USA, particularly for Black compared with White patients, even after accounting for medical insurance status. Examples include poorer outcome and treatment of colorectal cancer Reference Feder, Crook, Magee, Banerjee, Timmis and Hemingway13 and less frequent use of newer drugs for ischaemic stroke. Reference Ball and Elixhauser14

Race and metabolism of psychotropics

Prescribing in psychiatry differs by race for a variety of reasons, not least because genetic variation can affect the metabolism of psychotropics. Many psychotropics are metabolised by the hepatic cytochrome P450 (CYP450) enzymes - a family of enzymes initially developed by animals over billions of years to detoxify plant toxins. This enzymatic system includes over 40 different enzymes but only 6 are responsible for almost all drug metabolism. Some of these enzymes are subject to genetic polymorphism and Black and minority ethnic groups have variants of these isoenzymes with different, often slower, activity. Specifically, CYP2D6, CYP2C9 and CYP2C19, enzymes that are important in metabolising numerous antidepressants, antipsychotics and benzodiazepines, can be polymorphic. This means that some populations may metabolise psychotropics more slowly than others resulting in higher plasma levels. Determining the effects of genetic polymorphism on CYP450 enzymes is difficult, as even interethnic differences can be marked - in Black individuals, poor metabolism of CYP2D6 occurs in 1.8% of Ethiopians compared with 19% of South Africans. Reference Johnston, Fung, Gillum, Smith, Brass and Lichtman15 Overall, there are probably fewer people with poor metabolism of CYP2D6 and CYP2C9 in Asian and Black populations than in White populations, Reference Bernard, Neville, Nguyen and Flockhart16 and a greater proportion of East Asians than Black and White people with poor metabolism of CYP2C19. Reference Baxter17,Reference Oesterheld, Wynn, Oesterheld, Cozza and Armstrong18 Ultra-extensive and intermediate metabolisers also exist and proportions of these also vary by ethnicity: for instance, over 50% of Asian people have intermediate metabolism of CYP2D6. Reference Johnston, Fung, Gillum, Smith, Brass and Lichtman15 Although one would expect that genetic polymorphism of CYP450 enzymes would have an important effect on dosing of psychotropics for Asians, it does not explain differences in prescribing between other ethnic groups. That is not to say that metabolising ability has no effect on dosing or adverse effects of medication (indeed, those with poor metabolism of CYP2D6 have a greater risk of developing tardive dyskinesia and experiencing extrapyramidal side-effects Reference Baxter17 ), but that an individual's own metabolising ability may be more important than their ethnicity alone. Currently in the UK, determining CYP450 polymorphisms is prohibitively expensive and is usually only possible within a clinical trial.

Race and psychotropic prescribing

Are there differences in prescribing of psychotropics in Black and minority ethnic groups that relate to prejudice rather than metabolism? Patients and carers seem to think so, 6,Reference Oesterheld, Wynn, Oesterheld, Cozza and Armstrong19 and, after the inquiry into the death of David Bennett, 20 the issue needed investigation. 1

Most of the studies examining psychotropic use by ethnicity have been completed in the USA. Differences in antipsychotic treatment by ethnicity include: an increased likelihood of receiving an antipsychotic, Reference Sallah, Sashidharan, Stone, Struthers and Blofeld21-Reference Flaskerud and Hu23 higher doses, Reference Szarek and Goethe24-Reference Delbello, Soutullo and Strakowski26 older drugs Reference Diaz and de Leon27,Reference Segal, Bola and Watson28 and more frequent use of depot formulations. Reference Walkup, McAlpine, Olfson, Labay, Boyer and Hansell29 Again, these differences are pronounced for Black compared with White patients. These studies analysed mostly large US databases and adjusted for only a few confounding factors affecting the prescribing of antipsychotics; many did not adjust for health insurance status. The healthcare systems of the UK and the USA differ markedly and have a profound effect on access to, and receipt of, treatment.

There are few UK studies examining ethnicity and antipsychotic use. One survey Reference Fleck, Hendricks, Delbello and Strakowski30 found no significant differences (after adjustment for five confounding variables) in doses of antipsychotics taken by Black and White patients. However, Black patients were more likely than White patients to be receiving a depot antipsychotic and at a significantly higher dose. Our cross-sectional surveys of antipsychotic prescribing quality and ethnicity have included large numbers of patients from three NHS trusts and accounted for multiple confounding factors. Reference Daumit, Crum, Guallar, Powe, Primm and Steinwachs31,Reference Kuno and Rothbard32 We found no significant differences between Black and White patients for antipsychotic dose, high dose (>100% of maximum dose) or type (typical or atypical) prescribed, even after adjustment for over 20 different confounding factors. However, both higher costs of antipsychotic medication and polypharmacy (>1 antipsychotic prescribed) were significantly more likely in Black patients. Reference Daumit, Crum, Guallar, Powe, Primm and Steinwachs31

Antidepressant treatment may also vary by ethnicity. Black and Asian patients, especially those living in areas of high ethnic density, are less likely than White patients to access care for depression Reference Lloyd and Moodley33 and to be prescribed an antidepressant. Reference Connolly, Rogers and Taylor34,Reference Connolly and Taylor35 Moreover, even in vascular disease, where depression is associated with higher mortality, rates of antidepressant use are much lower in Black compared with White patients even after adjustment for depression severity. Reference Alegria, Chatterji, Wells, Cao, Chen and Takeuchi36 On the other hand, a study of psychiatrists' assessments of video vignettes of late-life depression in individuals who differed by gender and race (African American or White) found no differences in diagnosis or treatment. Reference Gonzalez, Croghan, West, Williams, Nesse and Tarraf37 This suggests that factors other than bias by race are also important. Racial differences in acceptability Reference Walters, Ashworth and Tylee38 of use of antidepressants have been cited as a potential cause of these findings. However, antidepressant stigma appears to be greater in White compared with Black patients. Reference Waldman, Blumenthal, Babyak, Sherwood, Sketch and Davidson39

Conclusions

It is clear that there is quite some way to go before UK health services provide equal treatment to all minority ethnic groups. However, prescribing of antipsychotics appears overall to be broadly equitable in minority ethnic groups. Further investigation of the potentially complex and numerous reasons for these differences is urgently needed.

Footnotes

Declaration of interest

A.C. has received lecturing honoraria and/or research funding from Lundbeck and Pfizer.

References

1 Department of Health. Delivering Race Equality in Mental Health Care: An Action Plan for Reform Inside and Outside Services and the Government's Response to the Independent Inquiry into the Death of David Bennett. Department of Health, 2005.Google Scholar
2 Singh, SP, Greenwood, N, White, S, Churchill, R. Ethnicity and the Mental Health Act 1983. Br J Psychiatry 2007; 191: 99105.Google Scholar
3 Care Quality Commission. Count Me In 2009. Results of the 2009 National Census of Inpatients in Mental Health and Learning Disability Services in England and Wales. Care Quality Commission, 2009.Google Scholar
4 Leese, M, Thornicroft, G, Shaw, J, Thomas, S, Mohan, R, Harty, MA, et al. Ethnic differences among patients in high-security psychiatric hospitals in England. Br J Psychiatry 2006; 188: 380–5.Google Scholar
5 Kirkbride, JB, Fearon, P, Morgan, C, Dazzan, P, Morgan, K, Tarrasch, R. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes. Findings from the 3-centre AESOP study. Arch Gen Psychiatry 2006; 63: 250–8.CrossRefGoogle Scholar
6 Department of Health. Inside Outside: Improving Mental Health Services for Black and Minority Ethnic Communities in England. Department of Health, 2003.Google Scholar
7 Singh, SP, Burns, T. Race and mental health: there is more to race than racism. BMJ 2006; 333: 648–51.CrossRefGoogle ScholarPubMed
8 Singh, SP. Institutional racism in psychiatry: lessons from inquiries. Psychiatr Bull 2007; 31: 363–5.Google Scholar
9 Murray, RM, Feron, P. Searching for racists under the psychiatric bed. Commentary on … Institutional racism in psychiatry. Psychiatr Bull 2007; 31: 365–6.Google Scholar
10 McKenzie, K, Bhui, K. Institutional racism in mental health care. BMJ 2007; 334: 649–50.CrossRefGoogle ScholarPubMed
11 Acheson, D. Independent Inquiry into Inequalities in Health Report. TSO (The Stationery Office), 1998.Google Scholar
12 Feder, G, Crook, AM, Magee, P, Banerjee, S, Timmis, AD, Hemingway, H. Ethnic differences in invasive management of coronary disease: prospective cohort study of patients undergoing angiography. BMJ 2002; 324: 511–6.Google Scholar
13 Ball, JK, Elixhauser, A. Treatment differences between blacks and whites with colorectal cancer. Med Care 1996; 34: 970–84.Google Scholar
14 Johnston, SC, Fung, LH, Gillum, LA, Smith, WS, Brass, LM, Lichtman, JH, et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke 2001; 32: 1061–8.Google Scholar
15 Bernard, S, Neville, KA, Nguyen, AT, Flockhart, DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications. Oncologist 2006; 11: 126–35.CrossRefGoogle ScholarPubMed
16 Baxter, K (ed). Stockley's Drug Interaction. Pharmaceutical Press, 2008.Google Scholar
17 Oesterheld, JR. 2D6. In Clinical Manual of Drug Interaction. Principles for Medical Practice (eds Wynn, GH, Oesterheld, JR, Cozza, KL, Armstrong, SC): 7798. American Psychiatric Publishing,, 2009.Google Scholar
18 Oesterheld, JR. 2C19. In Clinical Manual of Drug Interaction. Principles for Medical Practice (eds Wynn, GH, Oesterheld, JR, Cozza, KL, Armstrong, SC): 155–66. American Psychiatric Publishing,, 2009.Google Scholar
19 South London and Maudsley NHS Trust. Race Equality Scheme and Action Plan 2005–2008. South London and Maudsley NHS Trust, 2005.Google Scholar
20 Sallah, D, Sashidharan, S, Stone, R, Struthers, J, Blofeld, J. Independent Inquiry into the Death of David Bennett. Norfolk, Suffolk and Cambridgeshire Strategic Health Authority, 2003 (http://image.guardian.co.uk/sys-files/Society/documents/2004/02/12/Bennett.pdf).Google Scholar
21 Flaskerud, JH, Hu, LT. Racial/ethnic identity and amount and type of psychiatric treatment. Am J Psychiatry 1992; 149: 379–84.Google Scholar
22 Szarek, BL, Goethe, JW. Racial differences in use of antipsychotics among patients with bipolar disorder. J Clin Psychiatry 2003; 64: 614–5.CrossRefGoogle ScholarPubMed
23 Delbello, MP, Soutullo, CA, Strakowski, SM. Racial differences in treatment of adolescents with bipolar disorder. Am J Psychiatry 2000; 157: 837–8.Google Scholar
24 Diaz, FJ, de Leon, J. Excessive antipsychotic dosing in 2 US state hospitals. J Clin Psychiatry 2002; 63: 9981003.Google Scholar
25 Segal, SP, Bola, JR, Watson, MA. Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatr Serv 1996; 47: 282–6.Google Scholar
26 Walkup, JT, McAlpine, DD, Olfson, M, Labay, LE, Boyer, C, Hansell, S. Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry 2000; 61: 344–8.CrossRefGoogle ScholarPubMed
27 Fleck, DE, Hendricks, WL, Delbello, MP, Strakowski, SM. Differential prescription of maintenance antipsychotics to African American and white patients with new-onset bipolar disorder. J Clin Psychiatry 2002; 63: 658–64.Google Scholar
28 Daumit, GL, Crum, RM, Guallar, E, Powe, NR, Primm, AB, Steinwachs, DM, et al. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry 2003; 60: 121–8.Google Scholar
29 Kuno, E, Rothbard, AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry 2002; 159: 567–72.Google Scholar
30 Lloyd, K, Moodley, P. Psychotropic medication and ethnicity: an inpatient survey. Soc Psychiatry Psychiatr Epidemiol 1992; 27: 95101.Google Scholar
31 Connolly, A, Rogers, P, Taylor, D. Antipsychotic prescribing quality and ethnicity – a study of hospitalised patients in south east London. J Psychopharmacol 2007; 21: 191–7.Google Scholar
32 Connolly, A, Taylor, D. Ethnicity and quality of antipsychotic prescribing among in-patients in south London. Br J Psychiatry 2008; 193: 161–2.Google Scholar
33 Alegria, M, Chatterji, P, Wells, K, Cao, Z, Chen, CN, Takeuchi, D, et al. Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatr Serv 2008; 59: 1264–72.CrossRefGoogle ScholarPubMed
34 Gonzalez, HM, Croghan, T, West, B, Williams, D, Nesse, R, Tarraf, W, et al. Antidepressant use in black and white populations in the United States. Psychiatr Serv 2008; 59: 1131–8.CrossRefGoogle ScholarPubMed
35 Walters, P, Ashworth, M, Tylee, A. Ethnic density, physical illness, social deprivation and antidepressant prescribing in primary care: ecological study. Br J Psychiatry 2008; 193: 235–9.Google Scholar
36 Waldman, SV, Blumenthal, JA, Babyak, MA, Sherwood, A, Sketch, M, Davidson, J, et al. Ethnic differences in the treatment of depression in patients with ischemic heart disease. Am Heart J 2009; 157: 7783.Google Scholar
37 Kales, HC, Neighbors, HW, Blow, FC, Taylor, KK, Gillon, L, Welsh, DE, et al. Race, gender, and psychiatrists' diagnosis and treatment of major depression among elderly patients. Psychiatr Serv 2005; 56: 721–8.Google Scholar
38 Cooper, LA, Gonzales, JJ, Gallo, JJ, Rost, KM, Meredith, LS, Rubenstein, LV, et al. The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients. Med Care 2003; 41: 479–89.CrossRefGoogle ScholarPubMed
39 Givens, JL, Katz, IR, Bellamy, S, Holmes, WC. Stigma and the acceptability of depression treatments among African Americans and whites. J Gen Intern Med 2007; 22: 1292–7.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.